Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma

Ferenc Magyari, Sándor Barna, Kata Husi, Zsófia Simon, Zsófia Miltényi, László Váróczy, M. Udvardy, A. Illés

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective and importance: Hodgkin's lymphoma (HL) is a well-curable disease. The treatment usually includes combined multiagent conventional chemotherapy and radiotherapy. One-fifth of the patients need repeated treatments because of relapse or primary progressive disease. Those HL patients, who cannot be cured at least with salvage therapy (including autologous haemopoietic stem cell transplantation (auto-HSCT)), have really unfavourable prognosis. Intervention: For this heavily pretreated subset of HL patients, novel but less toxic treatment strategies should be considered. Brentuximab-vedotin (BV) is a novel targeted treatment option, which was administered after the failure of two different regimens in patients, who were ineligible for auto-HSCT or after the failure of auto-HSCT. Moreover, there are favourable data with chemotherapeutical regimens supplemented with rituximab not only in relapsed but also in newly diagnosed classical HL patients. Bendamustine, an almost forgotten 50-year-old drug, lives its renaissance in the twenty-first century, which can be administered in refractory HL as well. Combination of the ‘new’ and ‘old’ drugs might be also helpful. Conclusion: Our data suggest that rituximab plus bendamustine (supplemented with or without BV) could be a suitable alternative bridging salvage therapy for heavily pretreated HL patients.

Original languageEnglish
Pages (from-to)404-410
Number of pages7
JournalHematology
Volume21
Issue number7
DOIs
Publication statusPublished - Aug 8 2016

Fingerprint

Hodgkin Disease
Stem Cell Transplantation
Salvage Therapy
Poisons
Therapeutics
Pharmaceutical Preparations
Radiotherapy
Recurrence
Drug Therapy

Keywords

  • FDG-PET/CT
  • Bendamustine
  • Brentuximab-vedotin
  • Classical HL
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Magyari, F., Barna, S., Husi, K., Simon, Z., Miltényi, Z., Váróczy, L., ... Illés, A. (2016). Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma. Hematology, 21(7), 404-410. https://doi.org/10.1080/10245332.2015.1115192

Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma. / Magyari, Ferenc; Barna, Sándor; Husi, Kata; Simon, Zsófia; Miltényi, Zsófia; Váróczy, László; Udvardy, M.; Illés, A.

In: Hematology, Vol. 21, No. 7, 08.08.2016, p. 404-410.

Research output: Contribution to journalArticle

Magyari, F, Barna, S, Husi, K, Simon, Z, Miltényi, Z, Váróczy, L, Udvardy, M & Illés, A 2016, 'Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma', Hematology, vol. 21, no. 7, pp. 404-410. https://doi.org/10.1080/10245332.2015.1115192
Magyari F, Barna S, Husi K, Simon Z, Miltényi Z, Váróczy L et al. Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma. Hematology. 2016 Aug 8;21(7):404-410. https://doi.org/10.1080/10245332.2015.1115192
Magyari, Ferenc ; Barna, Sándor ; Husi, Kata ; Simon, Zsófia ; Miltényi, Zsófia ; Váróczy, László ; Udvardy, M. ; Illés, A. / Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma. In: Hematology. 2016 ; Vol. 21, No. 7. pp. 404-410.
@article{651edaa0b44b41ddbd62a3e0533b9415,
title = "Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma",
abstract = "Objective and importance: Hodgkin's lymphoma (HL) is a well-curable disease. The treatment usually includes combined multiagent conventional chemotherapy and radiotherapy. One-fifth of the patients need repeated treatments because of relapse or primary progressive disease. Those HL patients, who cannot be cured at least with salvage therapy (including autologous haemopoietic stem cell transplantation (auto-HSCT)), have really unfavourable prognosis. Intervention: For this heavily pretreated subset of HL patients, novel but less toxic treatment strategies should be considered. Brentuximab-vedotin (BV) is a novel targeted treatment option, which was administered after the failure of two different regimens in patients, who were ineligible for auto-HSCT or after the failure of auto-HSCT. Moreover, there are favourable data with chemotherapeutical regimens supplemented with rituximab not only in relapsed but also in newly diagnosed classical HL patients. Bendamustine, an almost forgotten 50-year-old drug, lives its renaissance in the twenty-first century, which can be administered in refractory HL as well. Combination of the ‘new’ and ‘old’ drugs might be also helpful. Conclusion: Our data suggest that rituximab plus bendamustine (supplemented with or without BV) could be a suitable alternative bridging salvage therapy for heavily pretreated HL patients.",
keywords = "FDG-PET/CT, Bendamustine, Brentuximab-vedotin, Classical HL, Rituximab",
author = "Ferenc Magyari and S{\'a}ndor Barna and Kata Husi and Zs{\'o}fia Simon and Zs{\'o}fia Milt{\'e}nyi and L{\'a}szl{\'o} V{\'a}r{\'o}czy and M. Udvardy and A. Ill{\'e}s",
year = "2016",
month = "8",
day = "8",
doi = "10.1080/10245332.2015.1115192",
language = "English",
volume = "21",
pages = "404--410",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma

AU - Magyari, Ferenc

AU - Barna, Sándor

AU - Husi, Kata

AU - Simon, Zsófia

AU - Miltényi, Zsófia

AU - Váróczy, László

AU - Udvardy, M.

AU - Illés, A.

PY - 2016/8/8

Y1 - 2016/8/8

N2 - Objective and importance: Hodgkin's lymphoma (HL) is a well-curable disease. The treatment usually includes combined multiagent conventional chemotherapy and radiotherapy. One-fifth of the patients need repeated treatments because of relapse or primary progressive disease. Those HL patients, who cannot be cured at least with salvage therapy (including autologous haemopoietic stem cell transplantation (auto-HSCT)), have really unfavourable prognosis. Intervention: For this heavily pretreated subset of HL patients, novel but less toxic treatment strategies should be considered. Brentuximab-vedotin (BV) is a novel targeted treatment option, which was administered after the failure of two different regimens in patients, who were ineligible for auto-HSCT or after the failure of auto-HSCT. Moreover, there are favourable data with chemotherapeutical regimens supplemented with rituximab not only in relapsed but also in newly diagnosed classical HL patients. Bendamustine, an almost forgotten 50-year-old drug, lives its renaissance in the twenty-first century, which can be administered in refractory HL as well. Combination of the ‘new’ and ‘old’ drugs might be also helpful. Conclusion: Our data suggest that rituximab plus bendamustine (supplemented with or without BV) could be a suitable alternative bridging salvage therapy for heavily pretreated HL patients.

AB - Objective and importance: Hodgkin's lymphoma (HL) is a well-curable disease. The treatment usually includes combined multiagent conventional chemotherapy and radiotherapy. One-fifth of the patients need repeated treatments because of relapse or primary progressive disease. Those HL patients, who cannot be cured at least with salvage therapy (including autologous haemopoietic stem cell transplantation (auto-HSCT)), have really unfavourable prognosis. Intervention: For this heavily pretreated subset of HL patients, novel but less toxic treatment strategies should be considered. Brentuximab-vedotin (BV) is a novel targeted treatment option, which was administered after the failure of two different regimens in patients, who were ineligible for auto-HSCT or after the failure of auto-HSCT. Moreover, there are favourable data with chemotherapeutical regimens supplemented with rituximab not only in relapsed but also in newly diagnosed classical HL patients. Bendamustine, an almost forgotten 50-year-old drug, lives its renaissance in the twenty-first century, which can be administered in refractory HL as well. Combination of the ‘new’ and ‘old’ drugs might be also helpful. Conclusion: Our data suggest that rituximab plus bendamustine (supplemented with or without BV) could be a suitable alternative bridging salvage therapy for heavily pretreated HL patients.

KW - FDG-PET/CT

KW - Bendamustine

KW - Brentuximab-vedotin

KW - Classical HL

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84978523903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978523903&partnerID=8YFLogxK

U2 - 10.1080/10245332.2015.1115192

DO - 10.1080/10245332.2015.1115192

M3 - Article

C2 - 26907830

AN - SCOPUS:84978523903

VL - 21

SP - 404

EP - 410

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 7

ER -